Page last updated: 2024-11-11

sr 31747

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

SR 31747: a sigma receptor antagonist and steroid isomerase inhibitor with immunosuppressive and anti-inflammatory activities; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID6439330
MeSH IDM0234097

Synonyms (22)

Synonym
132173-07-0
9k6u3i1ur0 ,
(z)-n-(3-(3-chloro-4-cyclohexylphenyl)-2-propenyl)-n-ethylcyclohexanamine hydrochloride
sr-31747
sr 31747
n-cyclohexyl-n-ethyl-3-(3-chloro-4-cyclohexylphenyl)propen-2-ylamine hydrochloride
cyclohexanamine, n-(3-(3-chloro-4-cyclohexylphenyl)-2-propenyl)-n-ethyl-, hydrochloride, (z)-
unii-9k6u3i1ur0
DB05792
arylacenamide
AKOS022180759
arylacenamide [who-dd]
cyclohexanamine, n-((2z)-3-(3-chloro-4-cyclohexylphenyl)-2-propen-1-yl)-n-ethyl-, hydrochloride (1:1)
(z)-n-(3-(3-chloro-4-cyclohexylphenyl)allyl)-n-ethylcyclohexanamine hydrochloride
sr31747a
sr-31747 hcl
HY-13751
Q27095695
CS-0007776
n-[(z)-3-(3-chloro-4-cyclohexylphenyl)prop-2-enyl]-n-ethylcyclohexanamine;hydrochloride
MS-26680
E87585

Research Excerpts

Overview

SR 31747 prevents the development of acute graft-versus-host reaction (GvHR) in hybrid B6D2F1 mice injected with C57BL/6 parental spleen cells. SR 31747 is a novel immunosuppressant agent that arrests cell proliferation in the yeast Saccharomyces cerevisiae.

ExcerptReferenceRelevance
"SR 31747A is a new sigma ligand eliciting immunosuppressive and anti-inflammatory properties. "( Enhancement of endotoxin-induced interleukin-10 production by SR 31747A, a sigma ligand.
Benoit, JM; Bouaboula, M; Bourrie, B; Casellas, P; Derocq, JM; Esclangon, M; Le Fur, G, 1995
)
1.97
"SR 31747 is a sigma ligand which prevents the development of acute graft-versus-host reaction (GvHR) in hybrid B6D2F1 mice injected with C57BL/6 parental spleen cells. "( The sigma ligand SR 31747 prevents the development of acute graft-versus-host disease in mice by blocking IFN-gamma and GM-CSF mRNA expression.
Bouaboula, M; Bourrie, B; Carayon, P; Casellas, P; Le Fur, G; Loubet, JF; Petitpretre, G, 1995
)
2.07
"SR 31747 is a novel immunosuppressant agent that arrests cell proliferation in the yeast Saccharomyces cerevisiae, SR 31747-treated cells accumulate the same aberrant sterols as those found in a mutant impaired in delta 8- delta 7-sterol isomerase. "( The immunosuppressant SR 31747 blocks cell proliferation by inhibiting a steroid isomerase in Saccharomyces cerevisiae.
Caput, D; Dhers, C; Dupuy, PH; Ferrara, P; Josse, A; Kaghad, M; Lanau, C; Le Fur, G; Leplatois, P; Loison, G; Picard, C; Rahier, A; Silve, S; Taton, M, 1996
)
2.05
"SR 31747 is a new sigma ligand which has immunosuppressive properties. "( In vivo effects of a new immunosuppressive sigma ligand, SR 31747, on mouse thymus.
Bourrie, B; Carayon, P; Casellas, P; Le Fur, G; Petitpretre, G, 1996
)
1.98
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (20)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's13 (65.00)18.2507
2000's7 (35.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.14

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.14 (24.57)
Research Supply Index3.09 (2.92)
Research Growth Index4.24 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.14)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (5.00%)5.53%
Reviews2 (10.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other17 (85.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Evaluation of Two Doses of SR31747A (75 mg and 125 mg) in Non-Metastatic Androgen-Independent Prostate Cancer. Randomized, Double-Blind, Placebo Controlled Phase II Study [NCT00174863]Phase 2232 participants (Actual)Interventional2003-10-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]